Compare Novo Nordisk A/S (NVO) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Phillips 66 — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Phillips 66 trades at $278.18 (market cap $112.36B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Phillips 66 for 62 Days on average.
| NVO | PSX | |
|---|---|---|
Market Cap | $165.31B | $112.36B |
Volume | 11,432,838 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $63.98 | $281.60 |
52-Week Low | $35.29 | $126.76 |
Typical Hold Time | 116 Days | 62 Days |
Enterprise Value | $179.56B | $128.83B |
Dividend Yield | 4.71% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Phillips 66 (PSX) trades at $281.60, up 3.67% over the past 24 hours and near its 52-week high, supported by bullish technical indicators and strong earnings beats in recent quarters. The company's fundamentals show solid profitability with a 4.66% net income margin and 24.02% ROE, while valuation ratios like a P/E of 16.07 and P/S of 0.75 appear reasonable. Recent news highlights structural strength in refining margins and AI-driven operational improvements.
The outlook for PSX is positive, driven by elevated refining crack spreads and debt-reduction progress, but risks include volatile energy prices and potential policy impacts on diesel exports. Analyst consensus leans bullish with a $279 price target, offering moderate upside from current levels amid robust institutional sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
